Ensysce Biosciences, Inc. (ENSC)

NASDAQ: ENSC · Real-Time Price · USD

0.547

+0.008 (1.52%)

At close: Mar 6, 2026, 4:00 PM EST

0.520

-0.027 (-4.95%)

After-hours: Mar 6, 2026, 7:59 PM EST

Ensysce Biosciences Employees

As of December 31, 2024, Ensysce Biosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.

Employees

Change (1Y)

Growth (1Y)

14.29%

Revenue / Employee

$560,997

Profits / Employee

-$1,371,559

Market Cap

1.99M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	8	1	14.29%
Dec 31, 2023	7	0	-
Dec 31, 2022	7	1	16.67%
Dec 31, 2021	6	3	100.00%
Dec 31, 2020	3	-	-

Related Stocks

Company Name	Employees
Lyra Therapeutics	30
Virax Biolabs Group	19
Azitra	12
CDT Equity	6
CNS Pharmaceuticals	5
Adial Pharmaceuticals	5
Artelo Biosciences	5
PMGC Holdings	3

Employee Rankings

ENSC News

3 days ago - Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans - Accesswire
4 days ago - Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology - Accesswire
8 days ago - Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
10 days ago - Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Accesswire
12 days ago - Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Accesswire
5 weeks ago - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain - Accesswire
6 weeks ago - Ensysce Biosciences Expands Global Opioid Patent Portfolio - Accesswire
2 months ago - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Accesswire

More News